In this webinar, discover how Artificial Intelligence (AI) is transforming early-phase drug development by enabling smarter, faster, and more cost-efficient decision-making. You’ll learn how predictive AI is being applied to tackle traditional synthesis challenges, identifying optimal chemical routes that reduce raw material costs and shorten development timelines. A real-world case study will demonstrate the tangible benefits of this data-driven approach.
The session will also explore how AI is transforming solid-form screening. By leveraging advanced machine learning models, Lonza scientists can accurately predict and identify the most stable cocrystal forms, enhancing efficiency and reducing development risks.
This webinar offers a practical roadmap for using AI to de-risk your small molecule programs and accelerate progress to the clinic.
Key Learning Objectives:
- Understand how AI can uncover more efficient and cost-effective synthesis routes
- Learn how machine learning predicts optimal crystal and cocrystal forms
- See how real-world case studies demonstrate measurable impact on speed and success